{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:20:24Z","timestamp":1793643624876,"version":"4.5.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.ejca.2011.06.056","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T19:25:49Z","timestamp":1311621949000},"page":"94-100","source":"Crossref","is-referenced-by-count":195,"title":["Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort"],"prefix":"10.1016","volume":"48","author":[{"given":"Lu","family":"Si","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2011.06.056_b0005","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2006.06.0442","article-title":"Toward a molecular classification of melanoma","volume":"25","author":"Fecher","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.06.056_b0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/327293a0","article-title":"Prevalence of ras gene mutations in human colorectal cancers","volume":"327","author":"Bos","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2011.06.056_b0205","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1128\/MCB.9.7.3114","article-title":"N-ras mutations in human cutaneous melanoma from sun-exposed body sites","volume":"9","author":"van \u2032t Veer","year":"1989","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ejca.2011.06.056_b0020","first-page":"1363","article-title":"Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype","volume":"4","author":"Albino","year":"1989","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2011.06.056_b0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/1523-1747.ep12371783","article-title":"Ras mutations in human melanoma: a marker of malignant progression","volume":"102","author":"Ball","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2011.06.056_b0030","first-page":"883","article-title":"Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma","volume":"149","author":"van Elsas","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejca.2011.06.056_b0035","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1046\/j.1523-1747.1998.00376.x","article-title":"N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin","volume":"111","author":"Jiveskog","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2011.06.056_b0040","first-page":"3468","article-title":"Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression","volume":"8","author":"Omholt","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.06.056_b0045","first-page":"6997","article-title":"BRAF and RAS mutations in human lung cancer and melanoma","volume":"62","author":"Brose","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2011.06.056_b0050","first-page":"3955","article-title":"Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues","volume":"63","author":"Gorden","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2011.06.056_b0055","first-page":"3362","article-title":"BRAF mutations in metastatic melanoma: a possible association with clinical outcome","volume":"9","author":"Kumar","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.06.056_b0060","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/1078-0432.CCR-1169-3","article-title":"Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas","volume":"10","author":"Shinozaki","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.06.056_b0065","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-3163-3-6","article-title":"Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis","volume":"3","author":"Houben","year":"2004","journal-title":"J Carcinog"},{"key":"10.1016\/j.ejca.2011.06.056_b0070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1479-5876-2-46","article-title":"Clinical significance of BRAF mutations in metastatic melanoma","volume":"2","author":"Chang","year":"2004","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2011.06.056_b0075","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.0022-202X.2005.23788.x","article-title":"BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival","volume":"125","author":"Akslen","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2011.06.056_b0080","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00008390-200510000-00011","article-title":"Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases","volume":"15","author":"Kirschner","year":"2005","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2011.06.056_b0085","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2011.06.056_b0090","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing","volume":"16","author":"Edlundh-Rose","year":"2006","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2011.06.056_b0095","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.jid.5700632","article-title":"Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma","volume":"127","author":"Liu","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2011.06.056_b0100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/jid.2009.182","article-title":"The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population","volume":"130","author":"Hacker","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2011.06.056_b0105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","article-title":"Clinical correlates of NRAS and BRAF mutations in primary human melanoma","volume":"17","author":"Ellerhorst","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.06.056_b0110","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.06.056_b0115","first-page":"10","article-title":"Skin cancer in individuals of African, Asian, Latin-American, and American-Indian descent: differences in incidence, clinical presentation, and survival compared to Caucasians","volume":"6","author":"Byrd-Miles","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ejca.2011.06.056_b0120","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1200\/JCO.2004.03.075","article-title":"Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry","volume":"22","author":"Eigentler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.06.056_b0125","doi-asserted-by":"crossref","unstructured":"Hardwicke J, Brunt AM, Rylands G, Rayatt S. Ten-year Audit of melanoma in a Central England population. Acta Derm Venereol 2011; (in press).","DOI":"10.2340\/00015555-1069"},{"key":"10.1016\/j.ejca.2011.06.056_b0130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10147-007-0751-1","article-title":"Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update","volume":"13","author":"Ishihara","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.06.056_b0135","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases","volume":"11","author":"Chi","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2011.06.056_b0140","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.06.056_b0145","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-10-2346","article-title":"Large scale analysis of KIT aberrations in Chinese patients with melanoma","volume":"17","author":"Kong","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.06.056_b0150","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2011.06.056_b0210","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.8503","article-title":"Phase I\/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors","volume":"28","author":"Kefford","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.06.056_b0160","first-page":"LBA27","article-title":"Phase 1\/2 study of GSK2118436, a selective inhibitor of V600 mutant (Mut) BRAF kinase: evidence of activity in melanoma brain metastases (Mets)","volume":"21","author":"Long","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2011.06.056_b0165","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1755-148X.2011.00837.x","article-title":"BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site","volume":"24","author":"Bauer","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ejca.2011.06.056_b0170","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/sj.jid.5700458","article-title":"Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation?","volume":"126","author":"Thomas","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2011.06.056_b0175","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/0008-5472.CAN-07-2615","article-title":"Modeling genomic diversity and tumor dependency in malignant melanoma","volume":"68","author":"Lin","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2011.06.056_b0180","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/jid.2009.287","article-title":"Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations","volume":"130","author":"Jovanovic","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2011.06.056_b0185","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/jid.2010.405","article-title":"BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han","volume":"131","author":"Qi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2011.06.056_b0190","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bjc.6603291","article-title":"Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis","volume":"95","author":"Eisen","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2011.06.056_b0195","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.0022-202x.2001.01601.x","article-title":"Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma","volume":"117","author":"Demunter","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2011.06.056_b0200","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.cmr.0000222600.73179.f3","article-title":"BRAF and NRAS mutations in melanoma and melanocytic nevi","volume":"16","author":"Poynter","year":"2006","journal-title":"Melanoma Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911004941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911004941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T09:25:26Z","timestamp":1560417926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911004941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0959804911004941"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.06.056","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}